A phase II trial of docetaxel plus cetuximab and docetaxel plus bortezomib (NSC #681239, IND #58443) in advanced non-small cell lung cancer patients with performance status (PS) 2.
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2013
At a glance
- Drugs Bortezomib (Primary) ; Cetuximab (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Aug 2009 Status changed from active, no longer recruiting to completed based on publication of final results.
- 24 Aug 2009 Results published in JCO.
- 24 Aug 2009 Primary endpoint 'progression free survival rate' has not been met.